Vascular Biogenics (VBLT)
NASDAQ:VBLT
VBLTVascular Biogenics
$2.26
-$0.14 (-5.83%)

Vascular Biogenics Stock Analysis & Ratings

Vascular Biogenics Stock Analysis Overview

Smart Score
7
Neutral
1
2
3
4
5
6
7
8
9
10
Learn more about TipRanks Smart Score
The Vascular Biogenics stock analysis is based on the TipRanks Smart Score which is derived from 8 unique data sets including Analyst recommendations, Crowd Wisdom, Hedge Fund Activity, Media Sentiment and multiple Technical stock factors. The Smart Score is a quantitative, data-driven rating system and does not include human intervention.

Stock Chart

VBLT

VBLT Stock Stats

Previous Close$2.4
Open$2.38
Bid2 x 100
Ask2.5 x 1000
Today’s Range$2.23 - $2.39
52-Week Range$1.01 - $3.17
Volume257.96K
Average Volume567.29K
Market Cap$136.24M
Beta0.97
P/E Ratio-4.3
EPS-0.53
Earnings DateAug 16, 2021

Company Description

Vascular Biogenics

Vascular Biogenics Ltd. is in the clinical-stage biopharmaceutical company, which engages in the discovery, development and commercialization of first-in-class treatments for cancer. It offers different programs for cancer and inflammatory disease patients such as vascular targeting system and Lecinoxoids. The company was founded by Dror Harats and Jacob George on January 27, 2000 and is headquartered in Modi'in, Israel.
Sector
Healthcare
Industry
Biotechnology
CEO
Dror Harats
Employees
38
Address
8 HaSatat Street, Modi'in, 7178106, IL

Financials


P/E Ratio Range

The price to earnings ratio. This is used by investors to assess a stock’s market price relative to its earnings.

VBLT FAQ

What was Vascular Biogenics’s price range in the past 12 months?
Vascular Biogenics lowest stock price was $1.01 and its highest was $3.17 in the past 12 months.
    What is Vascular Biogenics’s market cap?
    Vascular Biogenics’s market cap is $136.24M.
      What is Vascular Biogenics’s price target?
      The average price target for Vascular Biogenics is $5.50. This is based on 6 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
      The highest analyst price target is $7.00 ,the lowest forecast is $4.00. The average price target represents 143.36% Increase from the current price of $2.26.
        What do analysts say about Vascular Biogenics?
        Vascular Biogenics’s analyst rating consensus is a ‘Strong Buy. This is based on the ratings of 6 Wall Streets Analysts.
          When is Vascular Biogenics’s upcoming earnings report date?
          Vascular Biogenics’s upcoming earnings report date is Aug 16, 2021 which is in 20 days.
            How were Vascular Biogenics’s earnings last quarter?
            Vascular Biogenics released its earnings results on May 11, 2021. The company reported -$0.121 earnings per share for the quarter, beating the consensus estimate of -$0.13 by $0.009.
              Is Vascular Biogenics overvalued?
              According to Wall Street analysts Vascular Biogenics’s price is currently Undervalued.
                Does Vascular Biogenics pay dividends?
                Vascular Biogenics does not currently pay dividends.
                What is Vascular Biogenics’s EPS estimate?
                Vascular Biogenics’s EPS estimate for its next earnings report is not yet available.
                How many shares outstanding does Vascular Biogenics have?
                Vascular Biogenics has 60,290,000 shares outstanding.
                  What happened to Vascular Biogenics’s price movement after its last earnings report?
                  Vascular Biogenics reported an EPS of -$0.121 in its last earnings report, beating expectations of -$0.13. Following the earnings report the stock price went down -3.483%.
                    Which hedge fund is a major shareholder of Vascular Biogenics?
                    Currently, no hedge funds are holding shares in VBLT

                    What's Included in PREMIUM?
                    Make informed decisions based on Top Analysts' activity
                    Know what industry insiders are buying
                    Get actionable alerts from top Wall Street Analysts
                    Find out before anyone else which stock is going to shoot up
                    Get powerful stock screeners & detailed portfolio analysis